Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that both of its fully human monoclonal antibodies (mAbs) in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant. Moreover, both mAbs conferred complete protection against Omicron infected animals when given either parenterally or…
从这篇文章中可以得到什么：
- 一家专注于发现和开发新型抗感染疗法来治疗危及生命的感染的生物制药公司，今天宣布其 AR-701 鸡尾酒中的两种全人单克隆抗体 (mAb) 中和了 SARS-CoV-2 Omicron变体。
- Moreover, both mAbs conferred complete protection against Omicron infected animals when given either parenterally or….
- 订阅是免费的。
